Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Neurology

Psychosis

Dopamine D2 receptor; dopamine D3 receptor; serotonin (5-HT1A) receptor; serotonin (5-HT1B) receptor

In vitro and rodent studies suggest coumarin piperazine derivatives could be useful for treating psychosis. In vitro, members of the series bound to the serotonin (5-HT1A) and (5-HT1B) receptors and the dopamine D2 and D3 receptors with nanomolar and subnanomolar affinity. In mice and rats, the lead member of the series decreased multiple psychosis-associated behaviors compared with vehicle. Next steps include evaluating the lead coumarin piperazine derivative in additional preclinical studies.

SciBX 6(24); doi:10.1038/scibx.2013.607
Published online June 20, 2013

Patented; unavailable for licensing

Chen, Y. et al. J. Med. Chem.; published online May 15, 2013;
doi:10.1021/jm400408r
Contact: Guisen Zhang, Huazhong University of Science & Technology, Wuhan, China
e-mail:

gszhang@mail.hust.edu.cn